KCENTRA

This brand name is authorized in Japan, United States

Active ingredients

The drug KCENTRA contains a combination of these active pharmaceutical ingredients (APIs):

1 Prothrombin complex concentrate UNII FW411QXD5M - FACTOR IX COMPLEX

Read about Coagulation factor IX complex

2 Protein C UNII 3Z6S89TXPW - PROTEIN C

Protein C is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. Protein C exerts its effect by the inactivation of the activated forms of factors V and VIII which leads to a decrease in thrombin formation. Protein C has also been shown to have profibrinolytic effects. Read about Protein C

3 Protein S UNII 90J3F6N5FN - PROTEIN S HUMAN

Read about Protein S

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KCENTRA Powder for solution for infusion, lyophilized	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BD01	Coagulation factor IX, II, VII and X in combination	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: JP	医薬品医療機器総合機構	Identifier(s): 6343449D1024, 6343449D2020
Country: US	FDA, National Drug Code	Identifier(s): 63833-386, 63833-387, 63833-396, 63833-397, 63833-761